WO2005013951A3 - Compositions pharmaceutiques et methodes permettant de prevenir le cancer du sein et de l'ovaire - Google Patents

Compositions pharmaceutiques et methodes permettant de prevenir le cancer du sein et de l'ovaire Download PDF

Info

Publication number
WO2005013951A3
WO2005013951A3 PCT/PL2004/000063 PL2004000063W WO2005013951A3 WO 2005013951 A3 WO2005013951 A3 WO 2005013951A3 PL 2004000063 W PL2004000063 W PL 2004000063W WO 2005013951 A3 WO2005013951 A3 WO 2005013951A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical compositions
ovarian cancer
preventing breast
selenium
breast
Prior art date
Application number
PCT/PL2004/000063
Other languages
English (en)
Other versions
WO2005013951A2 (fr
Inventor
Jan Lubinski
Steven Narod
Stanislaw Zajaczek
Elzbieta Kowalska
Bohdan Gorski
Tomasz Huzarski
Tomasz Byrski
Jacek Gronwald
Jowita Huzarska
Barbara Gawronska-Szklarz
Original Assignee
Jan Lubinski
Steven Narod
Stanislaw Zajaczek
Elzbieta Kowalska
Bohdan Gorski
Tomasz Huzarski
Tomasz Byrski
Jacek Gronwald
Jowita Huzarska
Barbara Gawronska-Szklarz
Pomeranian Academy Of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jan Lubinski, Steven Narod, Stanislaw Zajaczek, Elzbieta Kowalska, Bohdan Gorski, Tomasz Huzarski, Tomasz Byrski, Jacek Gronwald, Jowita Huzarska, Barbara Gawronska-Szklarz, Pomeranian Academy Of Medicine filed Critical Jan Lubinski
Priority to EA200600386A priority Critical patent/EA200600386A1/ru
Priority to EP04775169A priority patent/EP1660060A2/fr
Priority to CA002535506A priority patent/CA2535506A1/fr
Priority to AU2004263070A priority patent/AU2004263070A1/en
Priority to JP2006523155A priority patent/JP2007502270A/ja
Publication of WO2005013951A2 publication Critical patent/WO2005013951A2/fr
Publication of WO2005013951A3 publication Critical patent/WO2005013951A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne des compositions pharmaceutiques de sélénium (ou leurs sels ou leurs dérivés ou tout autre composé comprenant du sélénium) et leurs méthodes d'utilisation afin de prévenir les cancers du sein/ovaire.
PCT/PL2004/000063 2003-08-11 2004-08-10 Compositions pharmaceutiques et methodes permettant de prevenir le cancer du sein et de l'ovaire WO2005013951A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EA200600386A EA200600386A1 (ru) 2003-08-11 2004-08-10 Фармацевтические композиции и способы предотвращения рака молочной железы и яичников
EP04775169A EP1660060A2 (fr) 2003-08-11 2004-08-10 Compositions pharmaceutiques et methodes permettant de prevenir le cancer du sein et de l'ovaire
CA002535506A CA2535506A1 (fr) 2003-08-11 2004-08-10 Compositions pharmaceutiques et methodes permettant de prevenir le cancer du sein et de l'ovaire
AU2004263070A AU2004263070A1 (en) 2003-08-11 2004-08-10 Pharmaceutical compositions for preventing breast and ovarian cancer
JP2006523155A JP2007502270A (ja) 2003-08-11 2004-08-10 乳癌および卵巣癌の予防のための医薬組成物および方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PLP.361597 2003-08-11
PL361597A PL214402B1 (pl) 2003-08-11 2003-08-11 Zastosowanie selenu albo jego zwiazku do otrzymywania srodka do obnizania odziedziczonego ryzyka zachorowania na raka piersi lub jajnika

Publications (2)

Publication Number Publication Date
WO2005013951A2 WO2005013951A2 (fr) 2005-02-17
WO2005013951A3 true WO2005013951A3 (fr) 2005-09-15

Family

ID=34132453

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PL2004/000063 WO2005013951A2 (fr) 2003-08-11 2004-08-10 Compositions pharmaceutiques et methodes permettant de prevenir le cancer du sein et de l'ovaire

Country Status (10)

Country Link
EP (1) EP1660060A2 (fr)
JP (1) JP2007502270A (fr)
KR (1) KR20060066719A (fr)
CN (1) CN1835740A (fr)
AU (1) AU2004263070A1 (fr)
CA (1) CA2535506A1 (fr)
EA (1) EA200600386A1 (fr)
PL (1) PL214402B1 (fr)
WO (1) WO2005013951A2 (fr)
ZA (1) ZA200602081B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080081039A1 (en) * 2004-09-21 2008-04-03 Velacor Therapeutics Pty. Ltd. Inorganic Selenium For Treatment Of Cancer
US20110117545A1 (en) * 2007-03-26 2011-05-19 Decode Genetics Ehf Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
CN100548311C (zh) * 2007-06-13 2009-10-14 中国科学技术大学 硒代硫酸钠在制备临床补硒和治疗癌症药物中的应用及快速制备方法
WO2009043106A1 (fr) * 2007-10-03 2009-04-09 Velacor Therapeutics Pty Ltd Sélénium inorganique et angiogenèse
EP2313529A2 (fr) * 2008-03-13 2011-04-27 Pomorska Akademia Medyczna Procédé visant à déterminer une prédisposition réduite au cancer, à partir du profil génétique
KR101026291B1 (ko) * 2008-06-30 2011-03-31 주식회사 태강 SeO2 doped W-Mo-Li 화합물을 함유한 항암제 조성물
GB0916010D0 (en) * 2009-09-11 2009-10-28 Isis Innovation JMJD2 demethylase inhibitors
WO2012067525A1 (fr) 2010-11-18 2012-05-24 Pomorski Uniwersytet Medyczny Génotypes et niveau de sélénium utilisés en tant que marqueurs du risque de cancer du sein/ovaire chez des sujets porteurs d'une mutation du gène brca1
AU2012237327B2 (en) 2011-04-01 2016-10-20 Iasomai Ab New combination comprising N-acetyl-L-cysteine and its use
CN114533753A (zh) 2013-03-15 2022-05-27 全技术公司 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用
MX2016011897A (es) * 2014-03-14 2017-04-27 Alltech Inc Composiciones de compuestos selenoorganicos y metodos de uso de los mismos.
PL442921A1 (pl) * 2022-11-23 2024-05-27 Read-Gene Spółka Akcyjna Obniżanie ryzyka zgonów u kobiet z dziedziczną predyspozycją do raka piersi

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064018A1 (fr) * 1998-06-09 1999-12-16 Biosyn Arzneimittel Gmbh Combinaison de composes contenant du selenium avec des agents cytostatiques

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064018A1 (fr) * 1998-06-09 1999-12-16 Biosyn Arzneimittel Gmbh Combinaison de composes contenant du selenium avec des agents cytostatiques

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
CAFFREY P B ET AL: "SELENITE CYTOTOXICITY IN DRUG RESISTANT AND NONRESISTANT HUMAN OVARIAN TUMOR CELLS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 52, no. 17, 1 September 1992 (1992-09-01), pages 4812 - 4816, XP008041713, ISSN: 0008-5472 *
CAFFREY P B ET AL: "SENSITIVITY OF MELPHALAN-RESISTANT TUMORS TO SELENITE IN VIVO", CANCER LETTERS, NEW YORK, NY, US, vol. 121, no. 2, 1997, pages 177 - 180, XP008041650, ISSN: 0304-3835 *
DAS, B. ET AL: "Regulation of growth and polyamine metabolism in MCF-7 human breast adenocarcinoma cells by selenium", INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES , 61(4), 213-218 CODEN: IJSIDW; ISSN: 0250-474X, 1999, XP008041662 *
DONG, YAN ET AL: "Identification of molecular targets associated with selenium-induced growth inhibition in human breast cells using cDNA microarrays", CANCER RESEARCH , 62(3), 708-714 CODEN: CNREA8; ISSN: 0008-5472, 2002, XP008041640 *
IP C ET AL: "MAMMARY CANCER PREVENTION BY REGULAR GARLIC AND SELENIUM-ENRICHED GARLIC", NUTRITION AND CANCER, LONDON, GB, vol. 17, no. 3, 1992, pages 279 - 286, XP002920430, ISSN: 0163-5581 *
IP C ET AL: "SELENIUM-ENRICHED GARLIC INHIBITS THE EARLY STAGE BUT NOT THE LATE STAGE OF MAMMARY CARCINOGENESIS", CARCINOGENESIS, IRL PRESS, LONDON, GB, vol. 17, no. 9, 1996, pages 1979 - 1982, XP008041663, ISSN: 0143-3334 *
IP, CLEMENT: "Anticarcinogenic effect of selenium in the dimethylbenz(a)anthracene- induced mammary tumor model in rats", JAOCS, J. AM. OIL CHEM. SOC. , 61(12), 1881-7 CODEN: JJASDH, 1984, XP008042181 *
KAECK, MARK ET AL: "Differential induction of growth arrest inducible genes by selenium compounds", BIOCHEMICAL PHARMACOLOGY , 53(7), 921-926 CODEN: BCPCA6; ISSN: 0006-2952, 1997, XP002315942 *
KOWALSKA E ET AL: "Increased rates of chromosome breakage in BRCA1 carriers are reduced by oral selenium supplementation", EJC SUPPLEMENTS, vol. 2, no. 3, March 2004 (2004-03-01), & EUROPEAN BREAST CANCER SCREENING GROUP MEETING - BREAST CANCER SCREENING IN EUROPE - CURRENT STATUS; MARCH 16-20, 2004, pages 186, XP008041608, ISSN: 1359-6349 *
MEDINA, D. ET AL: "Se-methylselenocysteine: A new compound for chemoprevention of breast cancer", NUTRITION AND CANCER , 40(1), 12-17 CODEN: NUCADQ; ISSN: 0163-5581, 2001, XP008041658 *
REDMAN, CLAIRE ET AL: "Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines", CANCER LETTERS (SHANNON, IRELAND) , 125(1,2), 103-110 CODEN: CALEDQ; ISSN: 0304-3835, 1998, XP008041649 *
RONAI, ZE'EV ET AL: "Effects of organic and inorganic selenium compounds on rat mammary tumor cells", INTERNATIONAL JOURNAL OF CANCER , 63(3), 428-34 CODEN: IJCNAW; ISSN: 0020-7136, 1995, XP008041677 *
SIEJA, KRZYSZTOF: "Selenium (Se) deficiency in women with ovarian cancer undergoing chemotherapy and the influence of supplementation with this micro-element on biochemical parameters", PHARMAZIE , 53(7), 473-476 CODEN: PHARAT; ISSN: 0031-7144, 1998, XP008041722 *
SINHA, R. ET AL: "Effects of methylselenocysteine on PKC activity, cdk2 phosphorylation and gadd gene expression in synchronized mouse mammary epithelial tumor cells", CANCER LETTERS (SHANNON, IRELAND) , 146(2), 135-145 CODEN: CALEDQ; ISSN: 0304-3835, 1999, XP008041646 *
YEO, JUN-KYU ET AL: "Se-methylselenocysteine induces apoptosis through caspase activation and Bax cleavage mediated by calpain in SKOV-3 ovarian cancer cells", CANCER LETTERS (SHANNON, IRELAND) , 182(1), 83-92 CODEN: CALEDQ; ISSN: 0304-3835, 2002, XP008041642 *
YUAN R ET AL: "Co-ordinate alterations in the expression of BRCA1, BRCA2, p300, and Rad51 in response to genotoxic and other stresses in human prostate cancer cells", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, no. 41, March 2000 (2000-03-01), & 91ST ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH.; SAN FRANCISCO, CALIFORNIA, USA; APRIL 01-05, 2000, pages 743, XP001182998, ISSN: 0197-016X *

Also Published As

Publication number Publication date
CN1835740A (zh) 2006-09-20
PL361597A1 (en) 2005-02-21
CA2535506A1 (fr) 2005-02-17
ZA200602081B (en) 2007-05-30
JP2007502270A (ja) 2007-02-08
AU2004263070A1 (en) 2005-02-17
EA200600386A1 (ru) 2006-12-29
EP1660060A2 (fr) 2006-05-31
PL214402B1 (pl) 2013-07-31
KR20060066719A (ko) 2006-06-16
WO2005013951A2 (fr) 2005-02-17

Similar Documents

Publication Publication Date Title
WO2005013951A3 (fr) Compositions pharmaceutiques et methodes permettant de prevenir le cancer du sein et de l'ovaire
IL184872A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
IL185063A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
HRP20060361A2 (en) Novel c-crystalline form of perindopril tert-butylamine salt, preparation method, and pharmaceutical compositions containing same
IL229975A0 (en) Pharmaceutical compounds containing arsenoic acid, its sodium salt and its antecedents for the treatment of organ cancer and its metastases
MXPA05010712A (es) Derivados de quinolin-2-ona para el tratamiento de enfermedades de las vias respiratorias.
IL180136A0 (en) 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
WO2003059898A3 (fr) Analogues d'eponemycine et d'epoxomicine et leurs utilisations
WO2005115470A3 (fr) COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE β-­CARBOLINE, ET LEUR UTILISATION POUR LE TRAITEMENT DES CANCERS
HK1085675A1 (en) Anticancer compounds
WO2004060264A3 (fr) Derives de metastine et utilisation associee
MX2021014680A (es) Derivado de benzotriazol.
IL159554A0 (en) Tricyclic imidazopyridine derivatives and pharmaceutical compositions containing the same
WO2006108488A8 (fr) Derives d'azole tricycliques, leur fabrication et leur utilisation en tant que principes pharmaceutiques
WO2004073375A8 (fr) Derives de podophyllotoxine utiles comme agents antitumoraux
NZ540972A (en) Novel 2,4-diamino-1,3,5-triazine derivative
AU2002357740A1 (en) Pyrazolo-pyridine derivatives as antiherpes agents
TW200612914A (en) Novel oxidized thioether derivatives, their manufacture and use as pharmaceutical agents
WO2002098399A3 (fr) Technique et compositions de traitement du cancer
WO2007001839A3 (fr) 4-anilino-3-quinolinecarbonitriles pour le traitement du cancer
WO2006076216A3 (fr) Complexes de coordination d'argent (i) antineoplastiques induisant l'apoptose
WO2003080624A3 (fr) Nouveaux dithiolopyrrolones ayant une action therapeutique
CA2407606A1 (fr) Phosphoramidates bis-(n,n'-bis-(2-haloethyl)amino) comme agents antitumoraux
TW200633701A (en) Thioether derivatives, their manufacture and use as pharmaceutical agents
WO2005105098A3 (fr) Preparation pour le traitement du cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480023124.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2535506

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/001632

Country of ref document: MX

Ref document number: 2006523155

Country of ref document: JP

Ref document number: 1020067002810

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200600386

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2004263070

Country of ref document: AU

Ref document number: 533/KOLNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004775169

Country of ref document: EP

Ref document number: 2006/02081

Country of ref document: ZA

Ref document number: 200602081

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2004263070

Country of ref document: AU

Date of ref document: 20040810

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004263070

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004775169

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067002810

Country of ref document: KR